Macroeconomic Woes, FX Headwind Drag NEOG Stock Down

Zacks01-03

Neogen's NEOG vast international trade is being impacted by global macroeconomic issues. Also, a tough competitive landscape weighs on the stock. NEOG stock carries a Zacks Rank #4 (Sell) currently. ...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2500145679?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-01-03 22:36","share_image_url":"https://static.laohu8.com/5f26f4a48f9cb3e29be4d71d3ba8c038","id":"2500145679","market":"us","top_or_hot":-1,"title":"Macroeconomic Woes, FX Headwind Drag NEOG Stock Down","media":"Zacks","content":"<div>\n<p>Neogen's NEOG vast international trade is being impacted by global macroeconomic issues. Also, a tough competitive landscape weighs on the stock. NEOG stock carries a Zacks Rank #4 (Sell) currently.\n...</p>\n\n<a href=\"https://finance.yahoo.com/news/macroeconomic-woes-fx-headwind-drag-143600709.html\">Source Link</a>\n\n</div>\n","source":"yahoofinance","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Macroeconomic Woes, FX Headwind Drag NEOG Stock Down</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nMacroeconomic Woes, FX Headwind Drag NEOG Stock Down\n</h2>\n\n<h4 class=\"meta\">\n\n\n2025-01-03 22:36 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://finance.yahoo.com/news/macroeconomic-woes-fx-headwind-drag-143600709.html><strong>Zacks</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Neogen's NEOG vast international trade is being impacted by global macroeconomic issues. Also, a tough competitive landscape weighs on the stock. NEOG stock carries a Zacks Rank #4 (Sell) currently.\n...</p>\n\n<a href=\"https://finance.yahoo.com/news/macroeconomic-woes-fx-headwind-drag-143600709.html\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LU1169590202.USD","symbol_name":"ALLSPRING (LUX)  U.S. SELECT EQUITY \"I\" (USD) ACC","start_time":0,"source_url":"https://finance.yahoo.com/news/macroeconomic-woes-fx-headwind-drag-143600709.html","article_id":"2500145679","we_media_id":null,"thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2500145679","pubTimestamp":1735914960,"columns":[],"sourceInfo":{"source_id":"yahoofinance","name":"雅虎金融"},"weMediaInfo":null,"summary":"Neogen's NEOG vast international trade is being impacted by global macroeconomic issues. Also, a tough competitive landscape weighs on the stock. NEOG stock carries a Zacks Rank #4  currently.Neogen’s international business continues to be affected due to currency movements. During the fiscal first quarter, the company faced a foreign currency headwind of 390 basis points.Further, Neogen faces intense competition from companies ranging from small businesses to divisions of large multinational companies. Some of these organizations have substantially greater financial resources than the company. Historically, Neogen has faced intense competition resulting from the development of new technologies by the company’s competitors, which could affect the marketability and profitability of Neogen’s products.Over the past three months, shares of NEOG have declined 20.8% compared with the industry’s 2.7% decline. With worldwide geopolitical issues getting complicated day by day, the company may c","collect":0,"end_time":0,"defaultTopTitle":"yahoo.com","property":[],"viewcount":null,"language":"en","relate_stocks":{"LU1169590202.USD":"ALLSPRING (LUX)  U.S. SELECT EQUITY \"I\" (USD) ACC","LU0106261612.USD":"SCHRODER ISF US SMALLER COMPANIES IMPACT \"A\" ACC","LU1169589451.USD":"ALLSPRING (LUX)  U.S. SELECT EQUITY \"A\" (USD) ACC","IE00B64QTZ34.USD":"NEUBERGER BERMAN US SMALL CAP \"A\" (USD) ACC","IE00BLDYK493.USD":"NEUBERGER BERMAN US SMALL CAP \"A\" (USD) INC","BK4139":"生物科技","HAE":"美国血液技术","LU0205194284.USD":"SCHRODER ISF US SMALL & MID-CAP EQUITY \"A\" (USD) INC AV","LU0205193047.USD":"SCHRODER ISF US SMALL & MID-CAP EQUITY \"A\" (USD)  ACC","BK4198":"医疗保健用品","NEOG":"纽尔真检测","PAHC":"Phibro Animal Health Corporation","BK4007":"制药","VCYT":"Veracyte Inc","LU2211817866.USD":"Allianz Food Security AT Acc USD","LU0012050646.USD":"SCHRODER ISF US SMALLER COMPANIES IMPACT \"A\" (USD) INC AV"},"translate_title":"宏观经济困境、外汇逆风拖累NEOG股价下跌","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"NEOG":1,"PAHC":1,"VCYT":1,"HAE":0.9},"content_text":"Neogen's NEOG vast international trade is being impacted by global macroeconomic issues. Also, a tough competitive landscape weighs on the stock. NEOG stock carries a Zacks Rank #4 (Sell) currently.\nFactors Pulling NEOG Stock Down\nNeogen’s international business continues to be affected due to currency movements. During the fiscal first quarter, the company faced a foreign currency headwind of 390 basis points. \nFurther, the current macroeconomic environment has been affecting Neogen’s financial operations. Governments and insurance companies continue to look for ways to contain the rising cost of healthcare. This might put pressure on players in the healthcare industry, with Neogen being no exception.  Although the company is gradually coming out of the impact of the two-and-a-half-year-long healthcare crisis, deteriorating international trade, with global inflationary pressure leading to a tough situation related to raw material and labor cost as well as freight charges and rising interest rate have put the medical device space in a tight spot.With sustained macroeconomic pressure, the company may struggle to keep its cost of revenues and operating expenses in check. In the fiscal first quarter of 2025, administrative expenses increased 14.5% from the prior-year quarter’s level to $51.7 million. Also, operating costs rose 5.2% year over year to $102.7 million. Our model forecasts a 0.5% rise in the metric for fiscal 2025.\nFurther, Neogen faces intense competition from companies ranging from small businesses to divisions of large multinational companies. Some of these organizations have substantially greater financial resources than the company. Historically, Neogen has faced intense competition resulting from the development of new technologies by the company’s competitors, which could affect the marketability and profitability of Neogen’s products.\n\nNeogen Corporation Price\n\nNeogen Corporation price | Neogen Corporation Quote\n\nOver the past three months, shares of NEOG have declined 20.8% compared with the industry’s 2.7% decline. With worldwide geopolitical issues getting complicated day by day, the company may continue to face supply related issues. Further, labor shortages and rising healthcare costs along with inflationary pressure might continue to dent Neogen’s profit margins. Accordingly, the stock might take time to regain its lost momentum.\nFactors Working in Favor of NEOG\nIn fiscal 2024, Neogen made a few significant launches, which include the new Molecular Detection Assay 2 – Salmonella Enteritidis/Salmonella Typhimurium (MDA2SEST) and CelluSmart technology (from Megazyme by Neogen). Additionally, the company launched the Petrifilm Automated Feeder to help labs efficiently process microbial tests and meet food safety standards. In April 2024, the company launched Neogen Farm Fluid MAX (in Great Britain) — a dual-action disinfectant designed for challenging farm conditions.\nNeogen is progressing well in terms of picking the right growth markets and gaining a bigger share of those markets. In the fiscal first quarter, the Indicator Testing, Culture Media & Other product category benefited from strong growth in the Petrifilm product line as well as solid growth in culture media and food quality nutritional analysis. Additionally, the Bacterial and General Sanitation product category saw modest growth in Pathogens. Also, the Natural Toxins and Allergens category experienced modest growth in Allergens but experienced a decline in Natural Toxins.\nThe company is expanding well in other geographies. The company is seeing double-digit sales growth in Latin America, with strong performance across most key product categories. \nKey Picks\nA few better-ranked stocks in the broader medical space are Veracyte VCYT, Haemonetics HAE and Phibro Animal Health PAHC.\nVeracyte has an estimated 2024 earnings growth rate of 37.2% compared with the industry’s 15.3%. Veracyte’s earnings surpassed the Zacks Consensus Estimate in each of the trailing four quarters, the average surprise being 520.6%. Its shares have risen 44.5% compared with the industry’s 3.6% growth in the past year. VCYT sports a Zacks Rank #1 (Strong Buy) at present. You can see the complete list of today’s Zacks #1 Rank stocks here.\nHaemonetics, carrying a Zacks Rank #2 (Buy) at present, has an estimated growth rate of 15.9% for fiscal 2025 earnings compared with the industry’s 12.3%. Shares of the company have fallen 8.3% against the industry’s 9.7% growth. HAE’s earnings surpassed estimates in three of the trailing four quarters and missed on one occasion, the average surprise being 2.82%.\nPhibro Animal Health, carrying a Zacks Rank #2 at present, has an estimated earnings growth rate of 35.3% for fiscal 2025 compared with the industry’s 11.1%. Shares of the company have risen 77.6% compared with the industry’s 9.8% growth over the past year. PAHC’s earnings surpassed estimates in each of the trailing four quarters, the average surprise being 25.47%.\nWant the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report\nHaemonetics Corporation (HAE) : Free Stock Analysis Report\nNeogen Corporation (NEOG) : Free Stock Analysis Report\nPhibro Animal Health Corporation (PAHC) : Free Stock Analysis Report\nVeracyte, Inc. (VCYT) : Free Stock Analysis Report\nTo read this article on Zacks.com click here.\nZacks Investment Research","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-1","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.30.0","shortVersion":"4.30.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2500145679"}